Search Breadcrumb Home Search Enter search keys … Jan 2019 J Immunother Cancer Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection Autoren Beyranvand Nejad E et al. Dec 2018 Clin Infect Dis Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2 Autoren Dejon-Agobe JC et al. Nov 2018 Immunobiology Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses Autoren Chissumba RM et al. Nov 2018 PLoS One Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design Autoren Viegas EO et al. Nov 2018 J Virol A measles virus-based vaccine candidate mediates protection against Zika virus in an allogenic mouse pregnancy mode Autoren Nürnberger C et al. Feb 2017 Nature Sterile protection against human malaria by chemoattenuated PfSPZ vaccine Autoren Mordmüller B ... Hoffmann SL Kremsner PG Aug 2017 Cell Rep Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV Autoren Rechtien A et al. Oct 2017 PLOS Med Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial Autoren Agnandji ST et al. Sep 2018 Vaccine Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV Autoren Fischer T et al. Jan 2017 Epidemiol Infect Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany. Autoren Schwarze-Zander C et al. Pagination Previous page ‹‹ Seite 32 Seite 33 Seite 34 Seite 35 Current page 36 Seite 37 Seite 38 Seite 39 Seite 40 Seite 32 Seite 33 Seite 34 Seite 35 Seite 36 Seite 37 Seite 38 Seite 39 Seite 40 Next page ››
Jan 2019 J Immunother Cancer Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection Autoren Beyranvand Nejad E et al.
Dec 2018 Clin Infect Dis Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2 Autoren Dejon-Agobe JC et al.
Nov 2018 Immunobiology Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses Autoren Chissumba RM et al.
Nov 2018 PLoS One Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design Autoren Viegas EO et al.
Nov 2018 J Virol A measles virus-based vaccine candidate mediates protection against Zika virus in an allogenic mouse pregnancy mode Autoren Nürnberger C et al.
Feb 2017 Nature Sterile protection against human malaria by chemoattenuated PfSPZ vaccine Autoren Mordmüller B ... Hoffmann SL Kremsner PG
Aug 2017 Cell Rep Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV Autoren Rechtien A et al.
Oct 2017 PLOS Med Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial Autoren Agnandji ST et al.
Sep 2018 Vaccine Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV Autoren Fischer T et al.
Jan 2017 Epidemiol Infect Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany. Autoren Schwarze-Zander C et al.
